Global Oncology Biosimilars Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Oncology Biosimilars Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Biosimilar is the identical copy of oncology biologics used for the treatment of cancer and officially approved for the treatment of cancer. These molecules are cost-effective, efficient, and have the same ability as biologics. These molecules are easy to manufacture as compared to biologics and can only be manufactured after patent expiry. Earlier there were various patented biologics available in the market but nowadays most of the patents have expired and few are on the verge of patent expiry. In the past few years, various biosimilars have been approved by FDA for the treatment of various types of cancer such as blood cancer, colorectal cancer, breast cancer, and others. In the near future, it is expected that a few more biosimilars will be introduced in the market thus supporting the growth of the market.
Oncology Biosimilars report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Oncology Biosimilars market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Retail Pharmacies and Hospital Pharmacy are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Oncology Biosimilars industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Oncology Biosimilars key companies include Celltrion, Biocon, Dr. Reddy’s Laboratories, STADA Arzneimittel AG, Intas Pharmaceuticals, Pfizer, Sandoz International, Teva Pharmaceutical Industries Ltd and Apotex, etc. Celltrion, Biocon, Dr. Reddy’s Laboratories are top 3 players and held % share in total in 2022.
Oncology Biosimilars can be divided into Monoclonal Antibody, Hematopoietic Agents, G-CSF and Others, etc. Monoclonal Antibody is the mainstream product in the market, accounting for % share globally in 2022.
Oncology Biosimilars is widely used in various fields, such as Retail Pharmacies, Hospital Pharmacy and Online Pharmacy,, etc. Retail Pharmacies provides greatest supports to the Oncology Biosimilars industry development. In 2022, global % share of Oncology Biosimilars went into Retail Pharmacies filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Oncology Biosimilars market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
Celltrion
Biocon
Dr. Reddy’s Laboratories
STADA Arzneimittel AG
Intas Pharmaceuticals
Pfizer
Sandoz International
Teva Pharmaceutical Industries Ltd
Apotex
BIOCAD
Segment by Type
Monoclonal Antibody
Hematopoietic Agents
G-CSF
Others
Retail Pharmacies
Hospital Pharmacy
Online Pharmacy
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Oncology Biosimilars market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Oncology Biosimilars introduction, etc. Oncology Biosimilars Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12QYResearch’s Conclusions of Oncology Biosimilars market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by QYResearch.
Oncology Biosimilars report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Oncology Biosimilars market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Retail Pharmacies and Hospital Pharmacy are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Oncology Biosimilars industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Oncology Biosimilars key companies include Celltrion, Biocon, Dr. Reddy’s Laboratories, STADA Arzneimittel AG, Intas Pharmaceuticals, Pfizer, Sandoz International, Teva Pharmaceutical Industries Ltd and Apotex, etc. Celltrion, Biocon, Dr. Reddy’s Laboratories are top 3 players and held % share in total in 2022.
Oncology Biosimilars can be divided into Monoclonal Antibody, Hematopoietic Agents, G-CSF and Others, etc. Monoclonal Antibody is the mainstream product in the market, accounting for % share globally in 2022.
Oncology Biosimilars is widely used in various fields, such as Retail Pharmacies, Hospital Pharmacy and Online Pharmacy,, etc. Retail Pharmacies provides greatest supports to the Oncology Biosimilars industry development. In 2022, global % share of Oncology Biosimilars went into Retail Pharmacies filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Oncology Biosimilars market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
Celltrion
Biocon
Dr. Reddy’s Laboratories
STADA Arzneimittel AG
Intas Pharmaceuticals
Pfizer
Sandoz International
Teva Pharmaceutical Industries Ltd
Apotex
BIOCAD
Segment by Type
Monoclonal Antibody
Hematopoietic Agents
G-CSF
Others
Segment by Application
Retail Pharmacies
Hospital Pharmacy
Online Pharmacy
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Oncology Biosimilars market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Oncology Biosimilars introduction, etc. Oncology Biosimilars Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12QYResearch’s Conclusions of Oncology Biosimilars market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices